Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma

Details for Australian Patent Application No. 2007296899 (hide)

Owner Istituto Nazionale per lo studio e la Cura dei Tumori Advanced Accelerator Applications SA

Inventors Di Cioccio Vito; Cattozzo, Margherita; Figini, Mariangela; Maurizi, Giovanni; Martin, Franck; Canevari, Silvana

Agent Griffith Hack

Pub. Number AU-B-2007296899

PCT Pub. Number WO2008/031577

Priority 06019399.2 15.09.06 EP

Filing date 12 September 2007

Wipo publication date 20 March 2008

Acceptance publication date 13 September 2012

International Classifications

C07K 16/30 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

26 March 2009 PCT application entered the National Phase

  PCT publication WO2008/031577 Priority application(s): WO2008/031577

14 January 2010 Assignment before Grant

  DOMPE PHA.R.MA S.P.A.; Istituto Nazionale per lo studio e la Cura dei Tumori The application has been assigned to Istituto Nazionale per lo studio e la Cura dei Tumori; Dompe' S.P.A.

23 August 2012 Alteration of Name

  The name of the applicant has been altered to Istituto Nazionale per lo studio e la Cura dei Tumori; Advanced Accelerator Applications SA 2009

13 September 2012 Application Accepted

  Published as AU-B-2007296899

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007296901-State sensor for plants, and irrigation system with such a state sensor

2007296889-Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors